Regeneron Pharmaceuticals (REGN) EBT (2009 - 2026)

Regeneron Pharmaceuticals' EBT history runs 18 years deep, the most recent figure standing at $831.2 million for Q1 2026.

• In Q1 2026, EBT fell 8.15% year-over-year to $831.2 million; the TTM figure through Mar 2026 stood at $5.2 billion (up 3.46% YoY), while the FY2025 annual figure was $5.2 billion, up 9.43% from the prior year.
• EBT was $831.2 million for Q1 2026 at Regeneron Pharmaceuticals, down from $1.0 billion in the prior quarter.
• In the past five years, EBT ranged from a high of $1.8 billion in Q3 2025 to a low of $700.7 million in Q1 2024.
• Historically, EBT has averaged $1.2 billion across 5 years, with a median of $1.1 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: EBT slumped 74.33% in 2022, then surged 50.35% in 2024.
• A 5-year view of EBT shows it stood at $1.3 billion in 2022, then fell by 13.37% to $1.1 billion in 2023, then fell by 16.51% to $958.1 million in 2024, then gained by 8.93% to $1.0 billion in 2025, then dropped by 20.36% to $831.2 million in 2026.
• The last three EBT figures came in at $831.2 million (Q1 2026), $1.0 billion (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.